TR199802238T2 - Treatment of asthma with TNFR-Ig. - Google Patents
Treatment of asthma with TNFR-Ig.Info
- Publication number
- TR199802238T2 TR199802238T2 TR1998/02238T TR9802238T TR199802238T2 TR 199802238 T2 TR199802238 T2 TR 199802238T2 TR 1998/02238 T TR1998/02238 T TR 1998/02238T TR 9802238 T TR9802238 T TR 9802238T TR 199802238 T2 TR199802238 T2 TR 199802238T2
- Authority
- TR
- Turkey
- Prior art keywords
- asthma
- treatment
- tnfalfa
- symmetrical
- binding protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Bu bulus p55 TNF reseptörünün eriyebilen kismini ve bir hümen IgG1 veya IgG3'ün agir zincirli sabit bölgesinin birinci alani hariç tutulmak üzere tüm alanlarini ihtiva eden simerik bir TNFalfa baglayici proteinin etkili bir miktarini ihtiva eden bir kompozisyon ile astim ile savasa yönelik bir metoda ve astimin tedavisine matuf bir ilacin hazirlanmasi için bu gibi simerik bir TNFalfa baglayici proteinin kullanimina yönelmistir.This invention is a method for the treatment of asthma and asthma, with a composition containing an effective amount of a symmetrical TNFalfa binding protein containing the soluble portion of the p55 TNF receptor and all areas of a humen IgG1 or IgG3 excluding the first domain of the heavy chain constant region. It directed towards the use of such a symmetrical TNFalfa binding protein for the preparation of a targeted drug.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1684296P | 1996-05-08 | 1996-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR199802238T2 true TR199802238T2 (en) | 1999-02-22 |
Family
ID=21779275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR1998/02238T TR199802238T2 (en) | 1996-05-08 | 1997-05-02 | Treatment of asthma with TNFR-Ig. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0910413A2 (en) |
JP (1) | JP2000510113A (en) |
KR (1) | KR20000010825A (en) |
CN (1) | CN1233189A (en) |
AR (1) | AR007020A1 (en) |
AU (1) | AU725408B2 (en) |
BR (1) | BR9708928A (en) |
CA (1) | CA2253557A1 (en) |
CO (1) | CO4820397A1 (en) |
HR (1) | HRP970224A2 (en) |
MA (1) | MA24169A1 (en) |
PE (1) | PE70698A1 (en) |
TR (1) | TR199802238T2 (en) |
WO (1) | WO1997041895A2 (en) |
ZA (1) | ZA973843B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1044267A2 (en) * | 1997-12-29 | 2000-10-18 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acid and polypeptide with homology to the tnf-receptors |
TR200504220T2 (en) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins. |
US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
DE602004013557D1 (en) * | 2003-02-28 | 2008-06-19 | Ares Trading Sa | LIQUID FORMULATIONS OF THE TUMORNEKROSE FRACTURE BINDING PROTEIN TBP-1 |
US7335491B2 (en) * | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
KR20090071652A (en) | 2006-10-20 | 2009-07-01 | 바이오겐 아이덱 엠에이 인코포레이티드 | Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59010908D1 (en) * | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-binding proteins |
NZ256293A (en) * | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
US5684222A (en) * | 1993-01-22 | 1997-11-04 | Ontario Cancer Institute | Mutant mouse having a disrupted TNFRp55 |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
CZ283219B6 (en) * | 1994-07-22 | 1998-02-18 | F. Hoffmann-La Roche Ag | Use of chimeric protein binding tnf in the preparation of a pharmaceutical preparation for treating auto-immune diseases |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
-
1997
- 1997-05-02 JP JP09539522A patent/JP2000510113A/en active Pending
- 1997-05-02 EP EP97921849A patent/EP0910413A2/en not_active Withdrawn
- 1997-05-02 KR KR1019980708961A patent/KR20000010825A/en not_active Application Discontinuation
- 1997-05-02 CN CN97194455A patent/CN1233189A/en active Pending
- 1997-05-02 BR BR9708928-1A patent/BR9708928A/en not_active Application Discontinuation
- 1997-05-02 AU AU27764/97A patent/AU725408B2/en not_active Ceased
- 1997-05-02 WO PCT/EP1997/002256 patent/WO1997041895A2/en not_active Application Discontinuation
- 1997-05-02 CA CA002253557A patent/CA2253557A1/en not_active Abandoned
- 1997-05-02 HR HR60/016,842A patent/HRP970224A2/en not_active Application Discontinuation
- 1997-05-02 MA MA24590A patent/MA24169A1/en unknown
- 1997-05-02 TR TR1998/02238T patent/TR199802238T2/en unknown
- 1997-05-05 ZA ZA9703843A patent/ZA973843B/en unknown
- 1997-05-05 PE PE1997000351A patent/PE70698A1/en not_active Application Discontinuation
- 1997-05-06 AR ARP970101876A patent/AR007020A1/en not_active Application Discontinuation
- 1997-05-07 CO CO97024335A patent/CO4820397A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR007020A1 (en) | 1999-10-13 |
PE70698A1 (en) | 1998-11-18 |
BR9708928A (en) | 2000-05-09 |
WO1997041895A2 (en) | 1997-11-13 |
MA24169A1 (en) | 1997-12-31 |
KR20000010825A (en) | 2000-02-25 |
HRP970224A2 (en) | 1998-04-30 |
CA2253557A1 (en) | 1997-11-13 |
WO1997041895A3 (en) | 1998-03-12 |
CN1233189A (en) | 1999-10-27 |
ZA973843B (en) | 1997-11-10 |
JP2000510113A (en) | 2000-08-08 |
EP0910413A2 (en) | 1999-04-28 |
AU2776497A (en) | 1997-11-26 |
AU725408B2 (en) | 2000-10-12 |
CO4820397A1 (en) | 1999-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998018826A3 (en) | Anti-CCR5 antibodies and methods of use therefor | |
ES2293973T3 (en) | ANTIBODIES ANTI-CCR2 HUMANIZED AND METHODS OF USE OF THE SAME. | |
ATE168013T1 (en) | HUMANIZED CHIMERA ANTI-''ICAM-1'' ANTIBODIES, PRODUCTION METHOD AND USE | |
EP1958965A3 (en) | Agonist antibodies to a musk receptor, and their therapeutic uses | |
EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
TR199800091T1 (en) | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies used as therapeutic agents for the treatment of immune diseases �. | |
ATE446973T1 (en) | ANTI-CCR2 ANTIBODIES AND THEIR USE | |
HK1015413A1 (en) | Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharaceutical compositions | |
DE69622074D1 (en) | Cystine-silicone copolymers and their use for the treatment of keratinous materials | |
DE69737592D1 (en) | MEDIUM AGAINST JUCKREIZ | |
PT800519E (en) | STEROID RECEPTOR MODULATORS AND METHODS | |
EP1106183A3 (en) | Antibodies to erbB2 and their therapeutic uses | |
DE69637781D1 (en) | FOR THE IL-13 RECEPTOR SPECIFIC CHIMERIC PROTEINS AND ITS USES | |
BR9106392A (en) | ANTI-ICAM-1 ANTIBODIES GRAFTED-HUMANIZED CDR, METHODS OF PREPARATION AND USE OF THE SAME | |
NZ329807A (en) | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome | |
TR199802238T2 (en) | Treatment of asthma with TNFR-Ig. | |
HK1025500A1 (en) | Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases | |
TR200001288T2 (en) | 2-arylbenzo (b) thiophene useful in the treatment of estrogen withdrawal syndrome. | |
GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
PT939809E (en) | TIE-2 RECEIVER LIGANDS (TIE LINK 3 AND TIE LINK 4) AND YOUR USES | |
AU1971295A (en) | Humanized monoclonal antibodies against human interleukin-4 | |
EP1028754A4 (en) | Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells | |
ES2130703T3 (en) | CONJUGATES OF BENZODIAZEPINES AND PROTEINS AND THEIR USE FOR THE IMMUNOLOGICAL DETERMINATION OF BENZODIAZEPINES. | |
DE60020970D1 (en) | MONOCLONAL ANTIBODY WITH SELECTIVE BINDING TO VGF AND USE FOR THE TREATMENT OF VGF DISEASES | |
MA26527A1 (en) | OLIGO-THIOPHENES SERVING AS ANTIMETASTATIC AGENTS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |